<DOC>
	<DOCNO>NCT02512302</DOCNO>
	<brief_summary>The purpose research study determine amount medicine absorb lung follow dose via eFlow nebulizer Seebri® Breezhaler® without activated charcoal subject moderate severe chronic obstructive pulmonary disease ( COPD ) .</brief_summary>
	<brief_title>Study Determine Amount Glycopyrrolate Absorbed Lungs After Taking Medicine With eFlow Nebulizer Seebri® Breezhaler® With Without Activated Charcoal Subjects With Moderate Severe Chronic Obstructive Pulmonary Disease ( COPD ) .</brief_title>
	<detailed_description>This randomize , open-label , single-dose per dose period , five-way crossover study subject 40 70 year age diagnosis moderate severe COPD per Global Initiative Chronic Obstructive Lung Disease guideline . After subject provide consent study participation , Screening Period last 3 week determine study eligibility allow appropriate washout prohibit medication . Eligible subject randomize one 10 treatment Sequences . There minimum 7-day washout period treatment visit . At visit , subject receive one dose study medication accord sequence assign . Subjects ≥ 20 % decrease forced expiratory volume one second ( FEV1 ) base review Visit predose value compare Screening value evaluate investigator continuation study . Subjects take theophylline able participate study .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<mesh_term>Charcoal</mesh_term>
	<criteria>1 . Male female patient 40 70 yearsold , inclusive . 2 . A clinical diagnosis moderate severe COPD accord GOLD 2014 guideline . 3 . Current smoker exsmokers least 10 packyear smoke history ( eg , least 1 pack/day 10 year , equivalent ) . 4 . Postbronchodilator ( follow inhalation ipratropium bromide ) FEV1 ≥ 30 % ≤ 80 % predict normal Screening Period . 5 . Postbronchodilator ( follow inhalation ipratropium bromide ) FEV1/FVC ratio ≤ 0.70 Screening Period . 6 . Ability perform reproducible spirometry accord American Thoracic Society ( ATS ) and/or European Respiratory Society ( ERS ) guideline ( 2005 ) . 7 . Subject , female ≤ 70 year age child bear potential , must negative urine pregnancy test Visit 1 . Females childbearing potential must instruct agree avoid pregnancy study must use acceptable method birth control : ) oral contraceptive , intrauterine device ( IUD ) , implantable contraceptive , transdermal injectable contraceptive least 1 month prior enter study continue use throughout study thirty day follow participation ; b ) barrier method contraception , eg , condom /or diaphragm spermicide participate study ; and/or c ) abstinence . 8 . Willing able remain study site least 24 hour treatment day . 9 . Willing able provide write informed consent . 10 . Willing able attend study visit adhere study assessment procedure . 1 . Severe comorbidities include unstable cardiac pulmonary disease medical condition would , opinion Investigator , preclude subject safely complete require test study , likely result disease progression would require withdrawal subject , include limited following : Unstable ischemic heart disease ( diagnosis myocardial infarction admission acute coronary syndrome ) within 6 month screen . Unstable cardiac arrhythmia heart failure ( change treatment plan ) within 6 month . Treatment diabetes mellitus within 6 month screen . 2 . Current evidence history clinically significant abnormality cardiac rhythm and/or conduction finding . 3 . Concomitant clinically significant respiratory disease COPD ( eg , asthma , tuberculosis , bronchiectasis , nonspecific pulmonary disease ) . 4 . History malignancy organ system treat untreated within past 5 year , exception localize basal cell carcinoma skin . 5 . Recent history COPD exacerbation require hospitalization need increase treatment COPD within 6 week prior Screening Period . 6 . Use daily oxygen therapy &gt; 10 hour per day . 7 . Use oral , intravenous , intramuscular steroid within 3 month prior Screening Period . 8 . Respiratory tract infection within 6 week prior Screening Period . 9 . Significant blood loss ( &gt; 500 mL ) donate blood within 60 day precede screen plan donate blood within 60 day complete study . 10 . History clinically significant ongoing bladder outflow obstruction history catheterization relief bladder outflow obstruction within previous 6 month . 11 . History narrowangle glaucoma . 12 . Prolonged QTc interval ( &gt; 450 msec male &gt; 470 msec female ) Screening Period , history long QT syndrome . 13 . Recent documented history ( previous 12 month ) substance abuse . 14 . .Positive urine drug screen Visit 1 provide subject unable produce valid medical rationale test result ( eg , prescription medication ) . 15 . Positive HbsAg , Hepatitis C antibody , HIV 1/2 antibody test Screening . 16 . History hypersensitivity intolerance aerosol medication , β2agonists , anticholinergic , sympathomimetic amine . 17 . Significant psychiatric disease would likely result subject able complete study , opinion Investigator . 18 . Participation another investigational drug study drug receive within 30 day prior Screening Period , current participation another investigational drug trial study treatment administer , include SUN101 study 19 . Previously receive SUN101 ( active treatment ; formerly know EP101 ) . 20 . Previously receive glycopyrrolate product within 28 day Screening . 21 . Subject take theophylline .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>COPD</keyword>
</DOC>